Embryonic folate metabolism and mouse neural tube defects

Science

Volumn 280, Issue 5372, 1998, Pages 2107-2109

  Fleming, Angeleen ^a   Copp, Andrew J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FOLIC ACID;

EMBRYO; EMBRYO DEVELOPMENT; FOLATE METABOLISM; MOUSE; NEURAL TUBE DEFECT; NEURULATION; NONHUMAN; PRIORITY JOURNAL; PYRIMIDINE SYNTHESIS; REVIEW;

ANIMALS; CENTRAL NERVOUS SYSTEM; DEOXYURACIL NUCLEOTIDES; DNA-BINDING PROTEINS; EMBRYO; FEMALE; FOLIC ACID; HUMANS; MALE; METHIONINE; MICE; MICE, INBRED CBA; MUTATION; NEURAL TUBE DEFECTS; PAIRED BOX TRANSCRIPTION FACTORS; PYRIMIDINES; TETRAHYDROFOLATES; THYMIDINE; THYMIDINE MONOPHOSPHATE; TRANSCRIPTION FACTORS;

EID: 0032568871     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.280.5372.2107     Document Type: Review

References (46)

1. R. W. Smithells et al., Arch. Dis. Child. 56, 911 (1981); N. Wald et al., Lancet 338, 131 (1991); A. E. Czeizel and I. Dudás, N. Engl. J. Med. 327, 1832 (1992).
2. R. W. Smithells et al., Arch. Dis. Child. 56, 911 (1981); N. Wald et al., Lancet 338, 131 (1991); A. E. Czeizel and I. Dudás, N. Engl. J. Med. 327, 1832 (1992).
3. R. W. Smithells et al., Arch. Dis. Child. 56, 911 (1981); N. Wald et al., Lancet 338, 131 (1991); A. E. Czeizel and I. Dudás, N. Engl. J. Med. 327, 1832 (1992).
4. E. B. Hook and A. E. Czeizel, Lancet 350, 513 (1997).
5. J. M. Scott et al., Ciba Foundation Symp. 181, 180 (1994).
6. M. K. Heid, N. D. Bills, S. H. Hinrichs, A. J. Clifford, J. Nutr. 122, 888 (1992); D. L. Cockroft, Hum. Reprod. 6, 148 (1991).
7. M. K. Heid, N. D. Bills, S. H. Hinrichs, A. J. Clifford, J. Nutr. 122, 888 (1992); D. L. Cockroft, Hum. Reprod. 6, 148 (1991).
8. P. N. Kirke et al., Q. J. Med. 86, 703 (1993); R. P. M. Steegers-Theunissen, G. H. J. Boers, F. J. M. Trijbels, T. K. A. B. Eskes, N. Engl. J. Med. 324, 199 (1991); J. L. Mills et al., Lancet 345, 149 (1995).
9. P. N. Kirke et al., Q. J. Med. 86, 703 (1993); R. P. M. Steegers-Theunissen, G. H. J. Boers, F. J. M. Trijbels, T. K. A. B. Eskes, N. Engl. J. Med. 324, 199 (1991); J. L. Mills et al., Lancet 345, 149 (1995).
10. P. N. Kirke et al., Q. J. Med. 86, 703 (1993); R. P. M. Steegers-Theunissen, G. H. J. Boers, F. J. M. Trijbels, T. K. A. B. Eskes, N. Engl. J. Med. 324, 199 (1991); J. L. Mills et al., Lancet 345, 149 (1995).
11. K. Morrison et al., J. Med. Genet. 34, 958 (1997).
12. J.M. Baden and M. Fujinaga, Br. J. Anaesth. 66, 500 (1991).
13. N. M. J. Van der Put et al., Lancet 346, 1070 (1995); A. S. Whitehead et al., Q. J. Med. 88, 763 (1995).
14. N. M. J. Van der Put et al., Lancet 346, 1070 (1995); A. S. Whitehead et al., Q. J. Med. 88, 763 (1995).
15. R. De Franchis, G. Sebastio, C. Mandata, G. Andria, P. Mastroiacovo, Lancet 346, 1703 (1995); D. E. L. Wilcken and X. L. Wang, ibid., 347, 340 (1996); C. Papapetrou, S. A. Lynch, J. Burn, Y. H. Edwards, ibid., 348, 58 (1996).
16. R. De Franchis, G. Sebastio, C. Mandata, G. Andria, P. Mastroiacovo, Lancet 346, 1703 (1995); D. E. L. Wilcken and X. L. Wang, ibid., 347, 340 (1996); C. Papapetrou, S. A. Lynch, J. Burn, Y. H. Edwards, ibid., 348, 58 (1996).
17. R. De Franchis, G. Sebastio, C. Mandata, G. Andria, P. Mastroiacovo, Lancet 346, 1703 (1995); D. E. L. Wilcken and X. L. Wang, ibid., 347, 340 (1996); C. Papapetrou, S. A. Lynch, J. Burn, Y. H. Edwards, ibid., 348, 58 (1996).
18. 3H]thymidine incorporation into DNA and for total protein content (bicinchoninic acid protein assay; Pierce). We performed the experiment on nine occasions, with n = 3 embryos per concentration.
19. To test antimetabolites, the dU suppression tests were performed with CD1 embryos, cultured in the presence of aminopterin (1 mg/ml), 5-fluorouracil (2 mg/ml), or cycloleucine (2 mg/ml) (minimum teratogenic doses established in preliminary studies). These experiments were performed on two to four occasions, with n = 3 embryos per group.
20. CD1 embryos were cultured from E8.5 to E9.5 in folate-deficient serum prepared by extensive dialysis of rat serum as described (20, 26) with addition of myo-inositol (10 μg/ml). Folic acid (1.0 mg/ml) was added to the control cultures. The experiment was performed on three occasions, with n = 6 embryos per group.
21. 2H allele was maintained on a mixed C3H/He, 101, and CBA/Ca background. Litters from heterozygote matings were genotyped by using a Pax3-specific polymerase chain reaction (PCR) (22). Lp/+ mice were produced by mating congenic LPT/Le congenic males with inbred CBA/Ca females (Harlan Olac, UK). Litters from heterozygote matings were genotyped by Crp PCR (27). All curly tail individuals were homozygous ct/ct, of which 45 to 55% exhibited tail defects or open spinal NTDs. Embryos were categorized as affected or unaffected on the basis of posterior neuropore length at the 27-to 29-somite stage (28). The dU suppression tests were performed on mutant embryos on four to seven occasions, with n = 3 to 6 embryos per group. Animal care was in accordance with UK governmental legislation (project licence 80/00503).
22. Splotch and CD1 embryos were cultured from E8.5 to E10.5 in the continuous presence of folic acid (200 μg/ml), thymidine (250 μg/ml), dUMP (500 μM), or methionine (1.5 mg/ml) (maximum nonteratogenic doses established in preliminary studies).
23. Pregnant splotch heterozygotes were injected intraperitoneally on E8.5 and E9.5 with folic acid or thymidine (each at 10 mg/kg body weight) or with an equivalent volume of PBS. Litters were collected at E12.5 or E13.5. We recorded the number of viable embryos and resorptions (no significant difference between groups, P > 0.05) and scored the embryos for cranial and spinal NTDs without knowledge of the treatment group. Figures of splotch embryos demonstrating prevention of NTDs by folic acid and thymidine are at: www.sciencemag.org/feature/data/981046.shl
24. L. A. G. J. M. VanAerts et al., Teratology 50, 348 (1994); T. H. Rosenquist, S. A. Ratashak, J. Selhub, Proc. Natl. Acad. Sci. U.S.A. 93, 15227 (1996).
25. L. A. G. J. M. VanAerts et al., Teratology 50, 348 (1994); T. H. Rosenquist, S. A. Ratashak, J. Selhub, Proc. Natl. Acad. Sci. U.S.A. 93, 15227 (1996).
26. J. D. Finkelstein, J. Nutr. Biochem. 1, 228 (1990). Additional information on pathways of folate metabolism are at: www.sciencemag.org/feature/data/ 981046.shl
27. Q. Zhao, R. R. Behringer, B. De Crombrugghe, Nature Genet. 13, 275 (1996); F. B. Essien and S. L. Wannberg, J. Nutr. 123, 27 (1993).
28. Q. Zhao, R. R. Behringer, B. De Crombrugghe, Nature Genet. 13, 275 (1996); F. B. Essien and S. L. Wannberg, J. Nutr. 123, 27 (1993).
29. M. J. Seller, Ciba Foundation Symp. 181, 161 (1994).
30. N. D. E. Greene and A. J. Copp, Nature Med. 3, 60 (1997).
31. M. I. Van Allen et al., Am. J. Med. Genet. 47, 723 (1993).
32. D. J. Epstein, M. Vekemans, P. Gros, Cell 67, 767 (1991).
33. G. Chalepakis, F. S. Jones, G. M. Edelman, P. Gruss, Proc. Natl. Acad. Sci. U.S.A. 91, 12745 (1994); G. M. Edelman and F. S. Jones, Philos. Trans. R. Soc. London 349, 305 (1995); G. Daston, E. Lamar, M. Olivier, M. Goulding, Development 122, 1017 (1996); S. Tajbakhsh, D. Rocancourt, G. Cossu, M. Buckingham, Cell 89, 127 (1997); M. Maroto et al., ibid., p. 139; D. J. Henderson and A. J. Copp, Mech. Dev. 69, 39 (1997).
34. G. Chalepakis, F. S. Jones, G. M. Edelman, P. Gruss, Proc. Natl. Acad. Sci. U.S.A. 91, 12745 (1994); G. M. Edelman and F. S. Jones, Philos. Trans. R. Soc. London 349, 305 (1995); G. Daston, E. Lamar, M. Olivier, M. Goulding, Development 122, 1017 (1996); S. Tajbakhsh, D. Rocancourt, G. Cossu, M. Buckingham, Cell 89, 127 (1997); M. Maroto et al., ibid., p. 139; D. J. Henderson and A. J. Copp, Mech. Dev. 69, 39 (1997).
35. G. Chalepakis, F. S. Jones, G. M. Edelman, P. Gruss, Proc. Natl. Acad. Sci. U.S.A. 91, 12745 (1994); G. M. Edelman and F. S. Jones, Philos. Trans. R. Soc. London 349, 305 (1995); G. Daston, E. Lamar, M. Olivier, M. Goulding, Development 122, 1017 (1996); S. Tajbakhsh, D. Rocancourt, G. Cossu, M. Buckingham, Cell 89, 127 (1997); M. Maroto et al., ibid., p. 139; D. J. Henderson and A. J. Copp, Mech. Dev. 69, 39 (1997).
36. G. Chalepakis, F. S. Jones, G. M. Edelman, P. Gruss, Proc. Natl. Acad. Sci. U.S.A. 91, 12745 (1994); G. M. Edelman and F. S. Jones, Philos. Trans. R. Soc. London 349, 305 (1995); G. Daston, E. Lamar, M. Olivier, M. Goulding, Development 122, 1017 (1996); S. Tajbakhsh, D. Rocancourt, G. Cossu, M. Buckingham, Cell 89, 127 (1997); M. Maroto et al., ibid., p. 139; D. J. Henderson and A. J. Copp, Mech. Dev. 69, 39 (1997).
37. G. Chalepakis, F. S. Jones, G. M. Edelman, P. Gruss, Proc. Natl. Acad. Sci. U.S.A. 91, 12745 (1994); G. M. Edelman and F. S. Jones, Philos. Trans. R. Soc. London 349, 305 (1995); G. Daston, E. Lamar, M. Olivier, M. Goulding, Development 122, 1017 (1996); S. Tajbakhsh, D. Rocancourt, G. Cossu, M. Buckingham, Cell 89, 127 (1997); M. Maroto et al., ibid., p. 139; D. J. Henderson and A. J. Copp, Mech. Dev. 69, 39 (1997).
38. G. Chalepakis, F. S. Jones, G. M. Edelman, P. Gruss, Proc. Natl. Acad. Sci. U.S.A. 91, 12745 (1994); G. M. Edelman and F. S. Jones, Philos. Trans. R. Soc. London 349, 305 (1995); G. Daston, E. Lamar, M. Olivier, M. Goulding, Development 122, 1017 (1996); S. Tajbakhsh, D. Rocancourt, G. Cossu, M. Buckingham, Cell 89, 127 (1997); M. Maroto et al., ibid., p. 139; D. J. Henderson and A. J. Copp, Mech. Dev. 69, 39 (1997).
39. M. D. Goulding, G. Chalepakis, U. Deutsch, J. R. Erselius, P. Gruss, EMBO J. 10, 1135 (1991).
40. A. P. Read and V. E. Newton, J. Med. Genet. 34, 656 (1997); S. Chatkupt et al., ibid. 32, 200 (1995).
41. A. P. Read and V. E. Newton, J. Med. Genet. 34, 656 (1997); S. Chatkupt et al., ibid. 32, 200 (1995).
42. D. L. Cockroft, in Postimplantation Mammalian Embryos: A Practical Approach, A. J. Copp and D. L. Cockroft, Eds. (IRL Press, Oxford, 1990), p. 15.
43. A. J. Copp, I. Checiu, J. N. Henson, Dev. Biol. 165, 20 (1994).
44. A. J. Copp, J. Embryol. Exp. Morphol. 88, 39 (1985).
45. C. Labarca and K. Paigen, Anal. Biochem. 102, 344 (1980).
46. We thank J. Scott and D. Henderson for valuable advice and critical reading of the manuscript. Supported by the Child Health Research Appeal Trust, the Wellcome Trust, the European Union, and the National Institutes of Child Health and Human Development, USA (Cooperative Agreement HD 28882).